Lamivudine Milpharm (Lamivudine)

Lamivudine is a nucleoside analogue that, after cellular phosphorylation, mimics natural nucleotides. When incorporated into viral DNA by reverse transcriptase, it terminates the growing DNA chain, preventing the virus from replicating its genome and thereby limiting infection.

The specific dose of Lamivudine Milpharm is determined by the prescribing clinician based on the patient’s condition, weight, renal function and other individual factors. Healthcare professionals set the appropriate regimen according to current treatment guidelines.

Safety data for lamivudine in pregnancy and lactation are limited. Clinicians must weigh the potential benefits for the mother against any unknown risks to the fetus or infant, and use the drug only when clearly indicated.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor class, offering a favorable safety profile and once‑daily dosing in many regimens. Compared with older NRTIs such as zidovudine, it has fewer mitochondrial toxicities, but it is often combined with other agents to achieve optimal viral suppression.

Lamivudine Milpharm should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its potency throughout its shelf life.

The medication is taken orally, usually as a tablet, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether the dose should be taken with meals to ensure consistent absorption.

Serious adverse events, although rare, include lactic acidosis, severe hepatotoxicity, and mitochondrial toxicity leading to peripheral neuropathy. Prompt medical evaluation is required if patients experience unexplained abdominal pain, rapid weight loss, or signs of liver dysfunction.

Lamivudine is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with severe renal impairment, active hepatitis, or those receiving interacting medications such as didanosine or stavudine.